Recent Development News: Q1 – 2015

Imprimis, Inc. and root9B Awarded a $1.7M NORTHCOM Industrial Control System Cybersecurity Contract

NEW YORK, March 2, 2015 /PRNewswire/ — NORAD-USNORTHCOM is the sponsoring defense agency for a $1.7M award through the Department of Defense Rapid Innovation Fund Program for an industrial control cyber security system to Imprimis, Inc. and root9B, a root9B … Continue reading

Posted in Recent Development News: Q1 - 2015 | Comments Off

Cerecor Bolsters Clinical Pipeline with Acquisition of Phase 2- ready Kappa Opioid Receptor Antagonist from Eli Lilly and Company

BALTIMORE, Feb 20, 2015 (BUSINESS WIRE) — Cerecor Inc, a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has acquired exclusive, worldwide rights from Eli … Continue reading

Posted in Recent Development News: Q1 - 2015 | Comments Off

Edge Therapeutics Reports Initial Data from its Phase 1/2 NEWTON Trial for EG-1962 for Improvement of Outcomes after Ruptured Brain Aneurysm

BERKELEY HEIGHTS, N.J.–(BUSINESS WIRE)– Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for the management of acute, life-threatening neurological conditions, today reported the progress of its ongoing Phase 1/2 NEWTON (Nimodipine microparticles … Continue reading

Posted in Recent Development News: Q1 - 2015 | Comments Off

root9B Technologies Acquires IPSA International; Also Announces $7.3 Million Investment from a Leading Financial Institution

NEW YORK, Feb. 10, 2015 /PRNewswire/ — root9B Technologies, Inc. (RTNB), a leading provider of cybersecurity and regulatory risk mitigation services, today announced that it has acquired privately-held IPSA International, Inc. (“IPSA”), a global business investigative and regulatory risk mitigation … Continue reading

Posted in Recent Development News: Q1 - 2015 | Comments Off

RestorGenex Granted Orphan Drug Designation for RES- 529 for Treatment of Glioblastoma Multiforme

BUFFALO GROVE, Ill., Jan. 28, 2015 (GLOBE NEWSWIRE) — RestorGenex Corporation (RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation … Continue reading

Posted in Recent Development News: Q1 - 2015 | Comments Off

RestorGenex Announces Presentation of Scientific Data on RES-529 for the Treatment of Glioblastoma at Keystone Symposia on PI 3-Kinase Signaling Pathways

BUFFALO GROVE, Ill., Jan. 23, 2015 (GLOBE NEWSWIRE) — RestorGenex Corporation (RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that it presented scientific data on RES-529 for the treatment of glioblastoma multiforme (GBM) … Continue reading

Posted in Recent Development News: Q1 - 2015 | Comments Off

Edge Therapeutics Announces Appointment of Renu Vaish, M.S. As Vice President, Regulatory Affairs

BERKELEY HEIGHTS, N.J., January 8, 2015 – Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming the treatment of acute, life-threatening neurological conditions, today announced that Renu Vaish, M.S. has … Continue reading

Posted in Recent Development News: Q1 - 2015 | Comments Off

ContraFect to Present Company Overview, Including Clinical Plan for CF-301, at the 7th Annual Biotech Showcase

YONKERS, NY–(Marketwired – Jan 7, 2015) – ContraFect Corporation(NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company’s chief executive … Continue reading

Posted in Recent Development News: Q1 - 2015 | Comments Off

RestorGenex Announces Issuance of European Patent for its Dermatology Program

Patent provides composition of matter and methods of use RestorGenex Corporation January 5, 2015 7:00 AM BUFFALO GROVE, Ill.–(BUSINESS WIRE)—RestorGenex Corporation (RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that the European … Continue reading

Posted in Recent Development News: Q1 - 2015 | Comments Off

SpendSmart doubles year-over-year with 3 Million Customers, 170 Licensees Rapid growth positions SpendSmart as the dominant provider of full-service mobile & loyalty solutions

SAN LUIS OBISPO, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) — via PRWEB – SMS Masterminds, a division of the publicly traded SpendSmart Networks, Inc. (SSPC) a national full-service mobile and loyalty marketing agency, started the new year off with over … Continue reading

Posted in Recent Development News: Q1 - 2015 | Comments Off

SpendSmart Creates New Masterminds Digital License Expands full-service offering to include responsive web design, reputation management

SAN LUIS OBISPO, Calif.—Jan. 5, 2015(BUSINESS WIRE)– SpendSmart Networks, Inc. (SSPC) (“SpendSmart” or “the Company”) today is announcing the release of a new license offering: the Masterminds Digital License. The new Digital License is anchored by a newly minted software … Continue reading

Posted in Recent Development News: Q1 - 2015 | Comments Off